Full View

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera… - ESC Heart …, 2022 - Wiley Online Library
Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …
被引用次数：15 相关文章

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.

V Visco, I Radano, A Campanile, A Ravera… - ESC Heart …, 2022 - europepmc.org
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …
[PDF] unina.it

[PDF][PDF] Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera, A Silverio… - 2022 - iris.unina.it
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera, A Silverio… - ESC, 2022 - Wiley Online Library
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …
[HTML] nih.gov

[HTML][HTML] Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera… - ESC Heart …, 2022 - ncbi.nlm.nih.gov
Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera… - ESC HEART …, 2022 - iris.unimol.it
Aims: The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …
[PDF] core.ac.uk

[PDF][PDF] Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera, A Silverio… - 2022 - core.ac.uk
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera… - ESC Heart …, 2022 - search.proquest.com
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile… - ESC heart …, 2022 - pubmed.ncbi.nlm.nih.gov
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

V Visco, I Radano, A Campanile, A Ravera… - ESC HEART …, 2022 - iris.unime.it
Aims The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …